Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry.

Background: Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines.Objectives: The object...

Descripción completa

Detalles Bibliográficos
Publicado en:American Heart Journal Vol. 170; no. 5; pp. 865 - 872
Autores principales: Navar, Ann Marie, Wang, Tracy Y., Goldberg, Anne C., Robinson, Jennifer G., Roger, Veronique L., Wilson, Peter F., Virani, Salim S., Elassal, Joesph, Lee, L. Veronica, Webb, Laura E., Peterson, Eric
Formato: research randomized controlled trial Journal Article
Publicado: Elsevier B.V. Nov2015
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Background: Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines.Objectives: The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals.Study Design: The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction.Conclusion: The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.